Regulatory approval

Published by the Health Canada.

Health Canada approved blinatumomab for the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

This is written in the approval document as:

BLINCYTO (blinatumomab for injection) is indicated for the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.

Citation

Amgen Canada Inc. Blincyto (blinatumomab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078156.PDF. Revised December 2024. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)